Status:
COMPLETED
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
Lead Sponsor:
Istanbul University
Conditions:
Nephrotic Syndrome
Glomerulonephritis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) an...
Detailed Description
Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. It is thought to be mainly a primary or idiopathic form; however, it may also be secondary to many other diseases (e.g., ...
Eligibility Criteria
Inclusion
- Age between 18-70 years
- Nondiabetic patients
- Patients with primary glomerulonephritis
- Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy
- Glomerular filtration rate \> 30 mL/min
- Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study
Exclusion
- Patients with secondary glomerulonephritis
- Glomerular filtration rate \< 30 mL/min
- Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study
- Patients with a history of gastric surgery
- Patients without an informed consent
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00983034
Start Date
March 1 2006
End Date
July 1 2009
Last Update
September 23 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University
Istanbul, Turkey (Türkiye), 34390